Peer-reviewed veterinary case report
Immunotherapy trial for dogs with atopic dermatitis from dust mites
By González, José-Luis et al.·Published in Veterinary dermatology·2018·Hospital Clí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells.
- Species:
- dog
Plain-English summary
Sixteen dogs with atopic dermatitis (a skin condition causing itching and inflammation) were treated with a new type of immunotherapy using a special allergen preparation. Over ten months, the dogs received injections that significantly reduced their itching, with most showing over 60% improvement in their symptoms within the first three months. There were no major side effects reported during the treatment. This suggests that this new immunotherapy could be a helpful option for managing atopic dermatitis in dogs.
People also search for: dog itching treatment · atopic dermatitis in dogs · immunotherapy for dog skin allergies
Abstract
BACKGROUND: Polymerized allergoids coupled to nonoxidized mannan (PM-allergoids) are novel allergen preparations used for immunotherapy. OBJECTIVE: To evaluate PM-allergoids as an alternative immunotherapy for dogs with canine atopic dermatitis (cAD) associated with serological responses to Dermatophagoides farinae allergens. ANIMALS: Sixteen dogs with history and clinical signs of cAD; positive on serum allergen specific IgE testing to D. farinae. Twelve dogs were, in addition, positive to Acarus siro and/or Lepidoglyphus destructor. METHODS AND MATERIALS: A prospective pilot study with no control group. PM-allergoids were administered by subcutaneous injection over a 10 month period. A pruritus Visual Analog Scale (pVAS) and medication scores were evaluated. Adverse reactions were recorded. RESULTS: The median value of the pVAS of the dogs decreased from 0.6 to 0.2 with a median of 67% improvement over the first three months (P < 0.0001). The individual improvement for each dog was greater than 60%. No major adverse effects were observed. CONCLUSIONS AND CLINICAL IMPORTANCE: Allergen-specific immunotherapy using an allergoid coupled to nonoxidized mannan may be an effective alternative for the management of cAD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30183126/